275 related articles for article (PubMed ID: 24439440)
1. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
Lalitha P; Sun CQ; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Cevallos V; McLeod SD; Acharya NR; Lietman TM;
Am J Ophthalmol; 2014 Feb; 157(2):318-26. PubMed ID: 24439440
[TBL] [Abstract][Full Text] [Related]
2. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.
Lalitha P; Prajna NV; Oldenburg CE; Srinivasan M; Krishnan T; Mascarenhas J; Vaitilingam CM; McLeod SD; Zegans ME; Porco TC; Acharya NR; Lietman TM
Cornea; 2012 Jun; 31(6):662-7. PubMed ID: 22333662
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials.
Prajna NV; Lalitha P; Krishnan T; Rajaraman R; Radnakrishnan N; Srinivasan M; Devi L; Das M; Liu Z; Zegans ME; Acharya NR; Porco TC; Lietman TM; Rose-Nussbaumer J
JAMA Ophthalmol; 2022 Feb; 140(2):179-184. PubMed ID: 35024776
[TBL] [Abstract][Full Text] [Related]
5. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.
Prajna NV; Krishnan T; Mascarenhas J; Rajaraman R; Prajna L; Srinivasan M; Raghavan A; Oldenburg CE; Ray KJ; Zegans ME; McLeod SD; Porco TC; Acharya NR; Lietman TM;
JAMA Ophthalmol; 2013 Apr; 131(4):422-9. PubMed ID: 23710492
[TBL] [Abstract][Full Text] [Related]
6. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
Sun CQ; Lalitha P; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Oldenburg CE; Ray KJ; McLeod SD; Acharya NR; Lietman TM;
Ophthalmology; 2014 Aug; 121(8):1495-500.e1. PubMed ID: 24746358
[TBL] [Abstract][Full Text] [Related]
7. Changing Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.
Prajna NV; Lalitha P; Rajaraman R; Krishnan T; Raghavan A; Srinivasan M; O'Brien KS; Zegans M; McLeod SD; Acharya NR; Keenan JD; Lietman TM; Rose-Nussbaumer J;
JAMA Ophthalmol; 2016 Jun; 134(6):693-6. PubMed ID: 27054515
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers.
Arora R; Gupta D; Goyal J; Kaur R
Clin Exp Ophthalmol; 2011 Jul; 39(5):434-40. PubMed ID: 21105974
[TBL] [Abstract][Full Text] [Related]
9. Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.
Gupta MK; Chandra A; Prakash P; Tilak R
J Mycol Med; 2018 Mar; 28(1):201-205. PubMed ID: 29398639
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
Vanathi M; Naik R; Sidhu N; Ahmed NH; Gupta N; Tandon R
Indian J Ophthalmol; 2022 Dec; 70(12):4270-4283. PubMed ID: 36453329
[TBL] [Abstract][Full Text] [Related]
11. Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.
Rose-Nussbaumer J; Prajna NV; Krishnan KT; Mascarenhas J; Rajaraman R; Srinivasan M; Raghavan A; Oldenburg CE; O'Brien KS; Ray KJ; McLeod SD; Porco TC; Lietman TM; Acharya NR; Keenan JD;
JAMA Ophthalmol; 2015 Jun; 133(6):642-6. PubMed ID: 25764482
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
13. Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method.
Wang L; Wang L; Han L; Yin W
Curr Eye Res; 2015; 40(11):1095-101. PubMed ID: 26268399
[TBL] [Abstract][Full Text] [Related]
14. Comparison of natamycin and voriconazole for the treatment of fungal keratitis.
Prajna NV; Mascarenhas J; Krishnan T; Reddy PR; Prajna L; Srinivasan M; Vaitilingam CM; Hong KC; Lee SM; McLeod SD; Zegans ME; Porco TC; Lietman TM; Acharya NR
Arch Ophthalmol; 2010 Jun; 128(6):672-8. PubMed ID: 20547942
[TBL] [Abstract][Full Text] [Related]
15. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs.
Shobana CS; Mythili A; Homa M; Galgóczy L; Priya R; Babu Singh YR; Panneerselvam K; Vágvölgyi C; Kredics L; Narendran V; Manikandan P
J Mycol Med; 2015 Mar; 25(1):44-9. PubMed ID: 25541256
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal susceptibility of Fusarium species and Aspergillus fumigatus cultured from eleven horses with fungal keratitis.
Martinez PS; Whitley RD; Plummer CE; Richardson RL; Hamor RE; Wellehan JFX
Vet Ophthalmol; 2022 Sep; 25(5):376-384. PubMed ID: 35684950
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activity of silver nanoparticles against ocular pathogenic filamentous fungi.
Xu Y; Gao C; Li X; He Y; Zhou L; Pang G; Sun S
J Ocul Pharmacol Ther; 2013 Mar; 29(2):270-4. PubMed ID: 23410063
[TBL] [Abstract][Full Text] [Related]
19. Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against
Rees CA; Bao R; Zegans ME; Cramer RA
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010869
[TBL] [Abstract][Full Text] [Related]
20. Benefit of polyhexamethylene biguanide in Fusarium keratitis.
Behrens-Baumann W; Seibold M; Hofmüller W; Walter S; Haeberle H; Wecke T; Tammer I; Tintelnot K
Ophthalmic Res; 2012; 48(4):171-6. PubMed ID: 22710976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
